Dr. Srividya N – Consultant Medical Oncologist
Dr. Srividya Nasaka is a renowned Consultant Medical Oncologist with over 10+ years of experience in the field. She is currently affiliated with Medicover Hospitals in Nellore, Andhra Pradesh. Her extensive experience spans various aspects of oncology, enabling her to provide expert care and treatment to cancer patients. Dr. Srividya is known for her compassionate approach and dedication to improving patient outcomes. At Medicover Hospitals, she utilizes the latest medical advancements to offer comprehensive cancer care.
Expertisation
Dr. Srividya N performs major interventions in the following medical specialties –
- Chemotherapy
- Targeted therapy Immunotherapy
- Colon and gastrointestinal cancer
- Kidney cancer and GU
- Breast cancer treatment
- Lung cancer
- Leukemia
- Lymphoma
- Myeloma
- Pediatric oncology
- Cancer screening
- Ovarian cancer
- Bone cancer
- Thyroid cancer Palliative treatment Transplantation
Education & Qualifications
- MBBS
- MD
- DM(Medical oncologists)
Work Experience
- 2012-2015 – Senior resident at Nims, Hyderabad
- 2015-2016 – Senior Resident at Ggh, Guntur
- 2015-2018 – Consultant Medical Oncologist at City Cancer Center, Vijayawada
- 2018- March 2021 – Consultant Medical Oncologist at Hcg, Vijayawada
- April 2021 -till date – Consultant Medical Oncologist Medicover Cancer Institute, Nellore
Publications
Dr Srividya N has authored several publications including –
- Response to imatinib mesylate in chronic phase childhood chronic myelogenous leukemia”, South Asian J Cancer 2014 Oct;3(4):203-5.
- Impact of imatinib adherence on cytogenetic response at six months in pediatric CP CML. Indian Journal of Pediatrics 2016 February 3. DOI 10.1007/s12098-015-2007-9.
- Impact of treatment protocol on outcomes of localized Ewing sarcoma. South Asian J Cancer 2016;5:194-5
- Trends in the management of acute lymphoblastic leukemia: Influence of adherence to insurance-based health care and treatment on outcomes of adolescents and adults with acute lymphoblastic leukemia. Indian J Med Paediatr Oncol 2016 January-March; 37 (1):32-7
- Cytogenetic and molecular response among EUTOS risk groups in children with CP CML under imatinib treatment. Egypt J Haematol 2017;42:74-7.
- Effectiveness of three prognostic scoring systems for predicting response and outcomes in pediatric CML CP on first-line imatinib. Indian J Med Paediatr Oncol 2017;38:282-6. Imatinib dose escalation in suboptimal response and failure in CP CML: results from a developing country. journal of clinical oncology 31,2013_suppl e18003
- Cytogenetic and Molecular Response Rates in PC AYA CML Patients on Imatinib Based on Baseline BMI”, Annals of Oncology, Volume 27, Issue suppl_9, December 2016, mdw586.009,
- Safety and effectiveness of carboplatin, capecitabine and cetuximab twice-weekly regimen in the first-line treatment of patients with recurrent/metastatic head and neck cancer (R/MSCCHN): a single-center retrospective study. Annals of Oncology, volume 29, number suppl_9, November 2018, mdy438.029.
- Prognostic significance of NLR kinetics in operable triple negative breast cancer. e14201 journal of clinical oncology 37,2019, no.15_suppl.
Memberships
- American Society of Clinical Oncology
- European Society of Medical Oncology
- Indian Society of Immuno-Oncology
Languages
- English
- Telugu
- Hindi
- Kannada